Brought to you by 
Series B brings in €14.1mm for ProtAffin
06 May 2009
Executive Summary
ProtAffin AG (developing therapeutics for cancer and inflammatory conditions) has raised €14.1mm ($18.4mm) through its Series B venture round. New investors Atlas Venture and SR One Ltd. co-led and were joined by current backers Aescap Venture, Entrepreneurs Fund, and Z-Cube. Atlas and SR One will each gain representation on the board. The proceeds will be used to finish preclinical studies and Phase I trials of PA401, ProtAffin's lead drug candidate for chronic and acute inflammation.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in €14.1mm for ProtAffin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice